FDA gets 30 days to approve new blood donation equipment—or explain why
H.R. 5791 — BLOOD Centers Act · Filed by Tony Wied (R-WI) · 17 cosponsors · Introduced Oct 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the FDA to create a fast-track approval process for blood centers that want to add new apheresis collection devices (machines that collect specific blood components) at existing locations. Blood centers that already operate multiple licensed sites or are accredited by recognized standards can get FDA approval within 30 days instead of the standard timeline, unless the FDA identifies specific safety concerns or a pattern of violations at that operator.
Why we flagged it
The bill's core mechanism is a regulatory streamlining measure—it creates a 30-day fast-track FDA approval pathway for blood collection device supplements at established blood centers. This is a procedural efficiency reform, not a deregulation or liability shield.
What the text implies
- The 30-day approval window is mandatory unless FDA documents specific safety concerns or systemic compliance failures, shifting the burden to FDA to justify delay rather than requiring applicants to prove safety—a subtle but meaningful procedural shift favoring applicants.
- Blood centers accredited by private accreditation organizations (not just FDA-licensed multi-site operators) qualify for expedited approval if their standards 'meet or exceed' FDA requirements, creating potential for regulatory arbitrage if accreditation standards diverge from FDA enforcement practice.
The full analysis lists 3 implications of this text.
Who stands to gain
established blood centers and blood collection operators; manufacturers of apheresis collection devices